Business Standard

SPONSORED CONTENT

What's this ?

Sponsored Content is a "Paid For" Press Release distribution arrangement. Purely a Commercial Arrangement, brands and advertisers pay to be featured and to get this content published.

The Editorial/Content team at Business Standard has not contributed to writing/editing this article.

To get your brand featured in this Section write to assist@bsmail.in

Converge Biotech announces the launch of Vergiflu (Favipiravir 200 mg) in India to treat mild to moderate Covid-19

ANI Press Release  |  Hyderabad (Telangana) [India]  

Tennis player James Blake
Arun Kumar Bijjala - Managing Director (Converge Biotech) with Vergiflu

Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India.

It will be marketed under the brand name 'VERGIFLU' and is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.

"We are delighted to announce the launch of Vergiflu for treatment of mild to moderate COVID-19 patients. At a time when cases are witnessing an alarming trend, our accelerated launch is aimed towards offering patients in India a much needed and timely therapy option. This strengthens our portfolio and keeps our commitment to bringing affordable therapy, accessible to patients," said Arun Kumar Bijjala, Managing Director of Converge Biotech Pvt Ltd.

Favipiravir is an off-patent; broad-spectrum oral anti-viral drug backed by strong clinical evidence and has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.

The drug is already approved for novel or re-emerging pandemic influenza virus infection in Japan since 2014, where high recovery rates have been reported with both 7 and 14 days of therapy in both mild and moderate patients.

The drug has shorter viral clearance and faster recovery rate and is reported to have a wide therapeutic safety margin for COVID-19 dose.

The mechanism of action of Favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells.

The drug has a high affinity to RNA virus-specific RNA polymerase and gets converted into an active phosphoribosylated form (favipiravir-RTP) in cells thereby inhibiting RNA polymerase activity.

The product is available from today in all major hospitals across the country. It will be sold only on prescription and the company will make sure that the drug is available to the patients.

Converge Biotech also has Prabinex HD (Injection vitamins c 1.5 g), Doxiverge (Inj Doxycycline 100 mg) and Oxihalt (Inj Glutathione 600mg) for hospitalized patients along with immunity boosters, Prabinex 500 mg (Tab Vitamin C 500mg) and Prabinex Z (Tab Vitamin C 500mg with Zinc 20mg); Divify (Vitamin D3 strips) and Tancyvit (Multivitamin).

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article.

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

Dear Reader,


Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, August 04 2020. 23:30 IST
RECOMMENDED FOR YOU

Converge Biotech announces the launch of Vergiflu (Favipiravir 200 mg) in India to treat mild to moderate Covid-19

Hyderabad (Telangana) [India] Aug 4 (ANI/BusinessWire India): Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India. Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India.

It will be marketed under the brand name 'VERGIFLU' and is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.

"We are delighted to announce the launch of Vergiflu for treatment of mild to moderate COVID-19 patients. At a time when cases are witnessing an alarming trend, our accelerated launch is aimed towards offering patients in India a much needed and timely therapy option. This strengthens our portfolio and keeps our commitment to bringing affordable therapy, accessible to patients," said Arun Kumar Bijjala, Managing Director of Converge Biotech Pvt Ltd.

Favipiravir is an off-patent; broad-spectrum oral anti-viral drug backed by strong clinical evidence and has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.

The drug is already approved for novel or re-emerging pandemic influenza virus infection in Japan since 2014, where high recovery rates have been reported with both 7 and 14 days of therapy in both mild and moderate patients.

The drug has shorter viral clearance and faster recovery rate and is reported to have a wide therapeutic safety margin for COVID-19 dose.

The mechanism of action of Favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells.

The drug has a high affinity to RNA virus-specific RNA polymerase and gets converted into an active phosphoribosylated form (favipiravir-RTP) in cells thereby inhibiting RNA polymerase activity.

The product is available from today in all major hospitals across the country. It will be sold only on prescription and the company will make sure that the drug is available to the patients.

Converge Biotech also has Prabinex HD (Injection vitamins c 1.5 g), Doxiverge (Inj Doxycycline 100 mg) and Oxihalt (Inj Glutathione 600mg) for hospitalized patients along with immunity boosters, Prabinex 500 mg (Tab Vitamin C 500mg) and Prabinex Z (Tab Vitamin C 500mg with Zinc 20mg); Divify (Vitamin D3 strips) and Tancyvit (Multivitamin).

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article.

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
image
Business Standard
177 22

Converge Biotech announces the launch of Vergiflu (Favipiravir 200 mg) in India to treat mild to moderate Covid-19

Converge Biotech, a leading healthcare company based at Hyderabad, today announces the launch of generic Favipiravir tablet in India.

It will be marketed under the brand name 'VERGIFLU' and is indicated for use in mild to moderate COVID-19 patients. Vergiflu is orally administered making it a convenient treatment option.

"We are delighted to announce the launch of Vergiflu for treatment of mild to moderate COVID-19 patients. At a time when cases are witnessing an alarming trend, our accelerated launch is aimed towards offering patients in India a much needed and timely therapy option. This strengthens our portfolio and keeps our commitment to bringing affordable therapy, accessible to patients," said Arun Kumar Bijjala, Managing Director of Converge Biotech Pvt Ltd.

Favipiravir is an off-patent; broad-spectrum oral anti-viral drug backed by strong clinical evidence and has been shown to hasten clinical recovery in COVID -19 patients with mild to moderate symptoms.

The drug is already approved for novel or re-emerging pandemic influenza virus infection in Japan since 2014, where high recovery rates have been reported with both 7 and 14 days of therapy in both mild and moderate patients.

The drug has shorter viral clearance and faster recovery rate and is reported to have a wide therapeutic safety margin for COVID-19 dose.

The mechanism of action of Favipiravir is novel compared to existing influenza antivirals that primarily prevent entry and exit of the virus from cells.

The drug has a high affinity to RNA virus-specific RNA polymerase and gets converted into an active phosphoribosylated form (favipiravir-RTP) in cells thereby inhibiting RNA polymerase activity.

The product is available from today in all major hospitals across the country. It will be sold only on prescription and the company will make sure that the drug is available to the patients.

Converge Biotech also has Prabinex HD (Injection vitamins c 1.5 g), Doxiverge (Inj Doxycycline 100 mg) and Oxihalt (Inj Glutathione 600mg) for hospitalized patients along with immunity boosters, Prabinex 500 mg (Tab Vitamin C 500mg) and Prabinex Z (Tab Vitamin C 500mg with Zinc 20mg); Divify (Vitamin D3 strips) and Tancyvit (Multivitamin).

This story is provided by BusinessWire India. ANI will not be responsible in any way for the content of this article.

DISCLAIMER


(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)

image
Business Standard
177 22